# Targeting Inflammation: Cytosporone B Modulates Imatinib-Driven Biochemical Alterations in Rat Heart

**Authors:** Denise Börzsei, András Nagy, Viktória Kiss, Zoltán Virág, Gyöngyi Kis, Nikoletta Almási, Szilvia Török, Médea Veszelka, Csaba Varga, Renáta Szabó

PMC · DOI: 10.3390/ijms262010018 · International Journal of Molecular Sciences · 2025-10-15

## TL;DR

This study shows that Cytosporone B can reduce heart inflammation caused by the chemotherapy drug Imatinib in rats.

## Contribution

Cytosporone B is shown to mitigate Imatinib-induced cardiac inflammation and oxidative stress in rats.

## Key findings

- Imatinib increased inflammatory and oxidative markers in rat hearts.
- Cytosporone B treatment reduced these Imatinib-induced elevations.
- Cytosporone B shows potential as a cardioprotective agent.

## Abstract

In recent decades, chemotherapy has significantly improved cancer survival, yet its adverse effects on non-cancerous tissues raise increasing concerns. In this context, growing attention has been focused on natural compounds that may be useful in mitigating the undesirable effects of chemotherapeutic agents. Here, we aimed to demonstrate that Cytosporone B (CsnB) is a potent agent for counteracting the cardiovascular effects induced by Imatinib. To this end, 12-week-old male Wistar rats were studied; they were divided into three groups as follows: (1) control, (2) Imatinib-treated (Imatinib: 60 mg/kg/day, per os), (3) Imatinib + CsnB-treated (CsnB: 5 mg/kg/day, i.p.). After the two-week-long experimental period, rats were euthanized. Their hearts were used for the following biochemical measurements: NADPH oxidase (NOX4), high mobility group box 1 (HMGB1), peptidylarginine deiminase 4 (PAD4), inducible nitric oxide synthase (iNOS) expression, tumor necrosis factor-alpha (TNF-α) level, and myeloperoxidase (MPO) activity. Imatinib caused a marked upregulation of key inflammatory and oxidative markers, including HMGB1, TNF-α, MPO, iNOS, PAD4, and NOX4 in cardiac tissue; however, CsnB treatment mitigated these elevations, implying its role in opposing Imatinib-induced inflammatory and oxidative processes in the heart. Our findings suggest that CsnB holds promise as a cardioprotective agent capable of modulating Imatinib-induced adverse cardiac effects.

## Linked entities

- **Genes:** HMGB1 (high mobility group box 1) [NCBI Gene 3146], TNF (tumor necrosis factor) [NCBI Gene 7124], NOX4 (NADPH oxidase 4) [NCBI Gene 50507], PADI4 (peptidyl arginine deiminase 4) [NCBI Gene 23569], NOS2 (nitric oxide synthase 2) [NCBI Gene 4843], MPO (myeloperoxidase) [NCBI Gene 4353]
- **Chemicals:** Cytosporone B (PubChem CID 10687292), Imatinib (PubChem CID 5291)

## Full-text entities

- **Genes:** Padi4 (peptidyl arginine deiminase 4) [NCBI Gene 29512] {aka Pdi4}, Tnf (tumor necrosis factor) [NCBI Gene 24835] {aka RATTNF, TNF-alpha, Tnfa}, Nox4 (NADPH oxidase 4) [NCBI Gene 85431], Nos2 (nitric oxide synthase 2) [NCBI Gene 24599] {aka Nos2a, iNos}, Mpo (myeloperoxidase) [NCBI Gene 303413], Hmgb1 (high mobility group box 1) [NCBI Gene 25459] {aka Ac2-008, Hmg1}
- **Diseases:** cancer (MESH:D009369), Inflammation (MESH:D007249)
- **Chemicals:** Cytosporone B (MESH:C531461)
- **Species:** Rattus norvegicus (brown rat, species) [taxon 10116]

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12564595/full.md

## Figures

6 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12564595/full.md

## References

42 references — full list in the complete paper: https://tomesphere.com/paper/PMC12564595/full.md

---
Source: https://tomesphere.com/paper/PMC12564595